Home / Peptides / Thymalin

Research review · Sources checked October 15, 2026

Thymalin: what the research shows

Thymalin is a polypeptide complex isolated from calf thymus by mild acid extraction and studied mainly in Russia as an immunomodulator. It is not an FDA-approved drug. It is not the same product as thymogen (the synthetic dipeptide L-Glu-L-Trp), which was isolated from thymalin and developed separately.[1][2]

What it is (and what it is not)

In a 1998 review, Morozov and Khavinson describe natural thymic peptides isolated from calf thymus, with a pharmaceutical preparation containing those peptides marketed as Thymalin. From that preparation they isolated the dipeptide L-Glu-L-Trp by reversed-phase HPLC; a synthetic pharmaceutical based on that dipeptide was named Thymogen. They also describe a related synthetic dipeptide termed Vilon. The paper states that both natural and synthetic products affected T-cell differentiation and lymphocyte cytokine responses in the authors’ work, and notes differences between natural and synthetic products.[1] This page is about the multi-peptide thymic complex (Thymalin), not thymogen or vilon alone.

Russian clinical and immunology reports

A 1989 Russian paper reported 35 patients with non-specific pulmonary disease: 21 received thymalin plus standard treatment and 14 were controls. The authors reported correction of decreased cellular-immunity markers (lymphocyte counts and OKT-4+/OKT-8+ proportions) without substantial effects on leukocyte chemotaxis/phagocytosis, immunoglobulins, or circulating immune complexes.[3] The abstract does not describe blinding or placebo control.

A 2002–2003 gerontology report from the St. Petersburg Institute of Bioregulation and Gerontology and a Ukrainian gerontology institute described long-term clinical assessment of Thymalin and Epithalamin in 266 elderly adults over 6–8 years (bioregulators applied in the first 2–3 years). The authors reported lower respiratory-disease incidence and lower mortality in peptide-treated groups versus controls, including larger reductions with combined Thymalin plus Epithalamin.[4] These claims come from the developing groups’ own long-term program; the PubMed abstract does not establish independent, blinded, multi-center confirmation.

COVID-era open-label trial

A 2021 single-center, open-label, prospective, randomized controlled trial in St. Petersburg hospitalized patients with confirmed COVID-19 compared standard care plus thymalin (n = 42) with standard care alone (n = 50). The published methods describe intramuscular thymalin for five days alongside guideline-based care. Authors reported faster declines in IL-6, C-reactive protein, and D-dimer and improved T-cell laboratory markers in the thymalin arm, and stated there were no deaths in either group during observation.[5] The trial was not blinded and reported laboratory and imaging markers rather than a pre-registered hard clinical primary endpoint with independent replication.

Regulatory status in the United States

No FDA-approved drug product containing thymalin appears in Drugs@FDA when searched via the openFDA drugsfda endpoint.[2] In a February 7, 2024 warning letter to US Chem Labs, FDA stated that products offered as “Thymalin” (along with semaglutide and tirzepatide) were unapproved new drugs and misbranded, that no approved applications under section 505 of the FD&C Act were in effect for those products, and that FDA was particularly concerned the firm marketed Thymalin for use in children without FDA evaluation of safety, effectiveness, or quality.[6] Thymalin does not appear on FDA’s public Category 2 compounding bulk-substance safety-risk list that names substances such as semax and epitalon; that absence is not an approval or a compounding authorization.[7]

What is not known

There are no independent, placebo-controlled Western trials establishing efficacy for infection, aging, or immune disease. Composition of commercial “thymalin” products sold outside Russian-registered manufacturing is not standardized by FDA. Long-term safety outside the Russian clinical literature is not well characterized in regulatory reviews.[4][5][6]

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend using, sourcing, or dosing any of these substances.